A carregar...
Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma
Rituximab-containing chemotherapy regimens constitute standard first-line therapy for mantle cell lymphoma (MCL). Since June 2013, 190 patients ≥18 years of age with MCL in British Columbia have been treated with bendamustine and rituximab (BR). The overall response rate to BR was 88% (54% complete...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7422137/ https://ncbi.nlm.nih.gov/pubmed/32735654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002068 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|